Molecular pathology selected abstracts
January 2026—Two studies investigated the use of DNA methylation patterns and sex-specific gene expression in neuroendocrine neoplasms (NEN) and Alzheimer disease, respectively.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Columns
Newsbytes
January 2026—The CAP Council on Informatics and Pathology Innovation (CIPI) launched the CIPI Connections podcast, focusing on informatics in pathology. The podcast, featuring episodes on various topics, aims to educate and introduce listeners to pathology innovators and thought leaders.
Q&A column
January 2026
Q. What is the CAP’s stance on antibody identification software, which is available via subscription, middleware, or an open-source platform? Read answer.
Q. Can toxicology testing be performed on a person who has been deceased for two years? Read answer.
Put It on the Board
January 2026—The CAP released a guideline for amyloidosis lab workup, recommending Congo red staining for amyloid detection and mass spectrometry for fibril protein typing. The guideline emphasizes the importance of accurate and timely identification of amyloid fibril types for effective treatment.
Challenges, and opportunities, abound
December 2025—When this column comes out, it will be nearly the end of 2025. It’s a good time to think about the challenges we have been facing—and the opportunities we will have in the coming years to address them. The CAP is no stranger to challenges, and neither are its members. There’s a lot going on in the world and in the health care markets that directly affects what we do. I believe that if we face these challenges head-on, we can find ways to improve laboratory quality and our ability to care for patients, all while strengthening the CAP as an organization.
Clinical pathology selected abstracts
December 2025—The American Gastroenterological Association formalized, in 2020, iron-deficiency anemia recommendations for postmenopausal women and for men, which include esophagogastroduodenoscopy and colonoscopy, or bidirectional endoscopy. This guideline only conditionally recommended that bidirectional endoscopy be performed on premenopausal women, who are more likely to have iron-deficiency anemia (IDA) due to menorrhagia. The association also advised revising the World Health Organization’s recommended iron-deficiency diagnostic threshold of 15 ng/mL or lower ferritin to 45 ng/mL or lower. The authors used population-representative data from the National Health and Nutrition Examination Survey (NHANES) to assess the role of these recommendations in IDA prevalence estimates and management in the United States.
Anatomic pathology selected abstracts
December 2025—Unusual morphologic patterns of breast carcinoma can raise diagnostic consideration for metastasis or special breast cancer subtypes and, thereby, impact clinical management and treatment. The authors conducted a study in which they described rare invasive breast cancers that mimic serous carcinoma of the gynecologic tract (serous-like breast carcinomas, SLBC) and characterized their clinicopathologic, immunophenotypic, and genetic features. The patients evaluated in the study were female (n = 15; median age, 49 years) and did not have a history of gynecologic malignancy. SLBC were characterized histologically by angulated, branched, sometimes anastomosing glands with micropapillary or pseudopapillary luminal projections in desmoplastic stroma. Most SLBC were triple negative (n = 10) or HER2 positive (n = 2) and grade 2 or 3, while some were estrogen receptor low positive/HER2 negative and low grade (n = 3). CK5/6 was positive irrespective of grade or receptor status (10 of 10).
Molecular pathology selected abstracts
December 2025—Two studies explore the evolution of Mycobacterium tuberculosis and the significance of GATA1 mutations in children with Down syndrome. The first study reveals diversity in virulence gene expression across Mtb clinical isolates, with variants in the regulator whiB6 linked to decreased expression of virulence factors and increased transmission of drug-resistant strains. The second study investigates the clinical significance of GATA1 mutations in neonates with Down syndrome, finding that the presence of GATA1s mutations at birth is a strong predictor of myeloid leukemia associated with Down syndrome (ML-DS).
Newsbytes
December 2025—Mayo Clinic recently introduced Mayo Clinic Platform_Insights, an offering designed to advance the adoption of artificial intelligence by giving health care organizations around the world access to Mayo Clinic’s digital expertise, data-driven insights, and clinical knowledge. “When organizations partner with us, they gain access to proven clinical and administrative solutions and the technical framework to integrate them seamlessly,” according to a press statement from Maneesh Goyal, chief operating officer for Mayo Clinic Platform, an initiative that brings together health systems, innovators, and researchers to support responsible AI development worldwide.
Q&A column
December 2025
Q. Now that the CMS allows direct observation for competency assessment to be performed virtually, does the CAP also allow it? If so, can you provide guidance? Read answer.
Q. We have implemented quality control at 10x in accordance with the Westgard rules. I use three levels of QC. If the results of two levels of QC are moving properly above and below the mean and only one level is showing a trend of a 10x rule violation, what corrective action should I take? Read answer.